Compare · CV vs TMDX
CV vs TMDX
Side-by-side comparison of CapsoVision Inc. (CV) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CV and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.37B, about 6.9x CV ($342.3M).
- Over the past year, CV is up 69.7% and TMDX is down 45.8% - CV leads by 115.5 points.
- TMDX has been more active in the news (12 items in the past 4 weeks vs 6 for CV).
- TMDX has more recent analyst coverage (18 ratings vs 2 for CV).
- Company
- CapsoVision Inc.
- TransMedics Group Inc.
- Price
- $6.80-1.80%
- $69.72+1.87%
- Market cap
- $342.3M
- $2.37B
- 1M return
- -3.75%
- -28.10%
- 1Y return
- +69.70%
- -45.80%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2019
- News (4w)
- 6
- 12
- Recent ratings
- 2
- 18
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest CV
- SEC Form 4 filed by Officer Wang Kang-Huai
- SEC Form 4 filed by Sr. VP of Finance Garcia David Michael
- SEC Form 4 filed by Head of Global Sales Atkinson Douglas Patrick
- SEC Form 10-Q filed by CapsoVision Inc.
- CapsoVision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- CapsoVision Reports First Quarter 2026 Financial Results
- Amendment: SEC Form SCHEDULE 13G/A filed by CapsoVision Inc.
- Head of Global Sales Atkinson Douglas Patrick exercised 107,357 shares at a strike of $0.42 (SEC Form 4)
- CapsoVision to Release First Quarter 2026 Financial Results on May 14, 2026
- SEC Form DEF 14A filed by CapsoVision Inc.
Latest TMDX
- SEC Form SD filed by TransMedics Group Inc.
- Director Basile Edward M was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Gunderson Thomas J. was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Raines Merilee was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Weill David was granted 2,922 shares, increasing direct ownership by 24% to 15,056 units (SEC Form 4)
- Director Lovell Stephanie was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Tobin James R was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Kania Edwin was granted 2,922 shares, increasing direct ownership by 1% to 263,732 units (SEC Form 4)
- Officer Forsyth Matthew S. was granted 15,409 shares (SEC Form 4)
- SEC Form 8-K filed by TransMedics Group Inc.